Navigation Links
BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
Date:3/8/2011

NEWARK, N.J. and LOUISVILLE, Ky., March 8, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTC Bulletin Board: BONU), a specialty life science technology-based company, today announced that it has received three new initial trial orders for its highly diverse Ogiene™ line of unregulated products.

The initial orders were made by Indiana-based Oakland City University, Kentucky-based Grayson County Fiscal Court House, and Exceptional Teens and Adults (ETA), which is a structured program providing care and support to teens and adults that have been diagnosed with intellectual or developmental disabilities.

The orders, which resulted from the BioNeutral executive team's recent trip to Kentucky, are the first in what is expected to be a long-term relationship with BioNeutral and its game changing line of products, for each organization involved.

The Ogiene™ odor eliminating product line has received acclaim in life sciences circles for its ability to neutralize odors with a dramatic increase in speed and power over its rivals in the marketplace. Its multi-purpose cleaner and stain remover has repeatedly proven its effectiveness and ease of use in direct consumer based field trials. Ogiene's™ proprietary technology platform has been proven highly effective in both surface and airborne applications. Other formulas that will soon be introduced into the market are the Sport Odor Eliminator (for use on all sports equipment), Graffiti Remover and White Board Rejuvenator. All of the Ogiene™ products are environmentally safe and do not harm the worlds food supply.

This announcement continues to build on the momentum which BioNeutral has achieved since the beginning of the year. Last week, the company announced that the EPA has granted its approval and registration (Reg No: 81242-1) for BioNeutral'sYgiene™ antimicrobial product line, after an intensive six month review & several years of R&D.

"We are pleased to see our efforts in Kentucky begin to show positive movement with these initial orders made by Oakland City University, Grayson County Fiscal Court House and Exceptional Teens and Adults, for our unregulated Ogiene line of products," said Stephen J. Browand President and CEO of BioNeutral Group, Inc. "Once people use these various Ogiene™ products in a real world application they quickly become believers, that our product claims are true."

About BioNeutral Group, Inc.Headquartered at the New Jersey Institute of Technology/EDC in Newark, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, Ygiene™ and Ogiene™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace.  BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have been approved by the EPA for sale in the United States and has previously  been approved for sale in Germany and it is also  permitted to be sold in the UK, France and Sweden. AutoNeutral is a Registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutralgroup.com.  

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393

Follow us on Twitter: http://twitter.com/bioneutralgroup

Forward-Looking StatementsThis release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene -206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and will soon be available for sale in the United States.PR CONTACT:Matt RizzettaNorth 6th Agencymrizzetta@north6thagency.com 718-744-7138IR CONTACT:Jeff RamsonProActive Capital Resources Group, LLCjramson@proactivecrg.com 212-792-4294  FOR THE COMPANY:Stephen J. BrowandBioNeutral Group, Inc.steve@bioneutralgroup.com 973-286-2899
'/>"/>

SOURCE BioNeutral Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutral Group to Receive Economic Development Incentives
2. Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
4. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
5. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
6. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
8. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
9. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
10. Photonic Products Group, Inc. Announces New Sales and Marketing VP
11. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)... Dec. 8, 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: ... develops and plans to commercialize innovative therapeutics for ... common stock were approved for trading on the ... on the OTCQX, effective today, under the ticker ... OTCQX market, companies must meet high financial standards, ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/8/2016)... 8, 2016   Biocept, Inc . (NASDAQ: ... of clinically actionable liquid biopsy tests to improve ... data featuring its Target Selector™ Circulating Tumor Cell ... the detection of actionable biomarkers in patients with ... by Sara Cannon Research Institute (SCRI), the research ...
Breaking Biology Technology:
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
(Date:12/5/2016)... -- The Office of Justice Programs, National Institute of ... or Replace Medico Legal Autopsies?" on NIJ.gov.  The ... forensic autopsies with postmortem X-ray computed tomography, commonly ... to recommendations made by The National Academy of ... a potential component of medicolegal death investigations. NIJ,s ...
Breaking Biology News(10 mins):